Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The AI IPO Wave Is The Dot-Com Bubble’s Evil Twin. Anthropic’s Delay Just Proved It.

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: The AI IPO Wave Is The Dot-Com Bubble’s Evil Twin. Anthropic’s Delay Just Proved It…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The AI IPO wave is the dot-com bubble's evil twin, and Anthropic's delay is a market message rather than a strategy.

    60% confidence
  • Anthropic's prospectus warns of "existential risks to humanity" from AI.

    60% confidence
  • Justifying a $2 trillion valuation requires an immediate 10% after-tax operating margin sustained for a decade, extraordinary revenue growth, and $358B in annual after-tax operating profit by 2035. It called the offering an unprecedented test of investor gullibility.

    60% confidence
  • Through 2030, AI data centers may generate at most $3.6 trillion in revenue versus the $8.5 trillion needed to cover planned investment, financing costs and a 12% return.

    60% confidence
  • 95% of organizations examined were getting no return from generative AI.

    60% confidence
  • Worldwide AI spending will reach $2.59 trillion in 2026, up 47% year over year.

    60% confidence
  • Just 7% of surveyed leaders say they have established ROI from AI.

    60% confidence
  • An IPO for OpenAI in 2026 would be ill-advised given AI safety concerns.

    60% confidence
  • Anthropic should pause its IPO, citing risks from increasingly autonomous AI systems that could behave unexpectedly and create security problems.

    60% confidence
  • Independent analysis puts Anthropic's comparable input and output pricing at roughly 18x and 23x DeepSeek R1's. Open-weight enterprise adoption rose from 23% to 67% in 2026 with 70%-90% cost savings, and the capability gap closes within six months of a frontier release.

    60% confidence
  • The biggest enterprise AI winners will own the architecture that turns any model into governed, auditable outcomes, not necessarily the most expensive model. The deployment is the product, not the model.

    60% confidence
  • Anthropic's $2 trillion valuation requires closed-model AI to keep a durable pricing premium over open-weight alternatives, and that premium is being dismantled.

    60% confidence
  • A quarter of Anthropic's 2025 revenue came from two unnamed customers. About 80% of its $518B infrastructure commitments are noncancelable or payable regardless of usage.

    60% confidence

Data points we hold from this source

Anthropic · ipo valuation target2000 USD
Anthropic · annualized revenue run rate67 USD
Anthropic · infrastructure commitments518 USD
Anthropic · noncancelable commitments share80 percent
Anthropic · noncash charge34 USD
Anthropic · net income-42 USD
Anthropic · compute infrastructure spend7.33 USD
Anthropic · customer concentration top two25 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com
The AI IPO Wave Is The Dot-Com Bubble’s Evil Twin. Anthropic’s Delay Just Proved It. — Source | Via News | Finance Via News